DCTH
Delcath Systems, Inc. NASDAQ$11.02
Mkt Cap $382.9M
52w Low $8.12
28.7% of range
52w High $18.23
50d MA $9.80
200d MA $10.19
P/E (TTM)
143.2x
EV/EBITDA
82.7x
P/B
3.5x
Debt/Equity
0.0x
ROE
2.4%
P/FCF
17.3x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$9.80
200d MA
$10.19
Avg Volume
417.6K
About
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.06 | -0.05 | +20.6% | 9.00 | +0.1% | -1.1% | -0.8% | -4.4% | +2.6% | +0.9% | -1.2% | — |
| Nov 4, 2025 | AMC | 0.02 | 0.02 | +0.0% | 9.08 | -1.7% | -4.4% | -4.8% | -4.8% | -5.5% | -5.1% | +10.4% | — |
| Aug 6, 2025 | AMC | 0.03 | 0.07 | +169.2% | 10.64 | +2.3% | -4.2% | -5.9% | -1.2% | +2.3% | +4.4% | +9.5% | — |
| May 8, 2025 | AMC | 0.10 | 0.03 | -70.0% | 14.36 | +0.1% | +3.3% | +0.6% | +6.5% | +7.7% | +11.8% | +11.1% | — |
| Mar 6, 2025 | AMC | -0.10 | 0.05 | +150.0% | 13.22 | +2.1% | -1.7% | -10.7% | -10.7% | -7.6% | -8.6% | -17.5% | — |
| Nov 8, 2024 | AMC | -0.13 | -0.03 | +76.9% | 11.06 | +1.8% | -9.9% | -12.3% | -14.9% | -16.5% | -15.1% | +4.7% | — |
| Aug 5, 2024 | AMC | -0.34 | -0.48 | -41.2% | 8.32 | +1.2% | -4.9% | -6.4% | -3.2% | -6.5% | -10.2% | +30.5% | — |
| May 14, 2024 | AMC | -0.43 | -0.43 | +0.0% | 7.07 | +4.8% | +1.7% | -1.6% | +7.1% | +13.6% | +14.4% | +5.0% | — |
| Mar 26, 2024 | AMC | -0.67 | -0.48 | +28.4% | 4.61 | +2.4% | +10.4% | +3.5% | +3.9% | +2.0% | +5.6% | +14.1% | — |
| Nov 13, 2023 | AMC | -0.51 | -0.61 | -19.6% | 2.98 | -1.0% | -24.5% | -20.8% | -17.1% | -17.8% | -9.4% | +9.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $10.21 | $9.43 | -7.6% | -11.9% | -12.8% | -12.5% | -15.8% | -9.6% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.21 | $10.31 | +1.0% | +1.3% | +0.8% | +2.1% | +1.7% | +0.0% |
| Nov 5 | Stephens & Co. | Maintains | Overweight → Overweight | — | $9.08 | $8.93 | -1.7% | -4.4% | -4.8% | -4.8% | -5.5% | -5.1% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $9.52 | $9.08 | -4.6% | -4.6% | -8.8% | -9.2% | -9.2% | -9.9% |
| Oct 21 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.42 | $11.40 | -0.2% | -0.3% | -9.3% | -9.1% | -10.4% | -12.5% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.97 | $10.54 | -11.9% | -4.6% | -4.8% | -13.5% | -13.3% | -14.5% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.64 | $10.89 | +2.3% | -4.2% | -5.9% | -1.2% | +2.3% | +4.4% |
| Jun 23 | Stephens & Co. | Maintains | Overweight → Overweight | — | $13.85 | $13.32 | -3.8% | -4.3% | +0.1% | +0.6% | +1.4% | -2.0% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.15 | $16.21 | +0.4% | -0.2% | +1.6% | +0.2% | +5.6% | +0.4% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.22 | $13.50 | +2.1% | -1.7% | -10.7% | -10.7% | -7.6% | -8.6% |
Recent Filings
8-K
Delcath Systems Inc -- 8-K Filing
Delcath Systems' percutaneous hepatic perfusion combined with ipilimumab and nivolumab showed promising results for metastatic uveal melanoma in the published CHOPIN Phase 2 trial, potentially supporting future development and commercialization efforts.
Mar 3
8-K
Delcath Systems Inc -- 8-K Filing
Delcath Systems reported its fourth quarter and full year 2025 financial results, with management hosting a conference call to discuss performance and outlook for the medical device company.
Feb 26
8-K · 5.02
!!! Very High
Nuwellis, Inc. -- 8-K 5.02: Executive Change
Nuwellis appointed Martin J. Emerson and David A. McDonald as Class I directors, potentially signaling board refreshment and strategic changes for the medical device company's governance structure.
Feb 26
Data updated apr 25, 2026 4:49am
· Source: massive.com